Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. Show more

Location: 3940 Trust Way, Hayward, CA, 94545, United States | Website: https://benitec.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

289.8M

52 Wk Range

$7.05 - $17.15

Previous Close

$11.74

Open

$11.87

Volume

98,447

Day Range

$11.03 - $11.96

Enterprise Value

196.9M

Cash

103.6M

Avg Qtr Burn

-4.667M

Insider Ownership

3.12%

Institutional Own.

85.16%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BB-301 Details Oculopharyngeal Muscular Dystrophy	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.